Break it Down: Cleo Diagnostics partnership to bring new hope for ovarian cancer detection

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on Cleo Diagnostics’ (ASX:COV) partnership with The Royal Women’s Hospital in Melbourne to participate in its ovarian cancer trial.

The company aims to bring to market a simple blood test for the accurate and early diagnosis of the cancer based on a novel patented biomarker.

Tune in to get the latest.